The Role of the ACE2/MasR Axis in Ischemic Stroke: New Insights for Therapy

Ischemic stroke remains the leading cause of neurologically based morbidity and mortality. Current stroke treatment is limited to two classes of FDA-approved drugs: thrombolytic agents (tissue plasminogen activator (tPA)) and antithrombotic agents (aspirin and heparin), which have a narrow time-wind...

Descripción completa

Detalles Bibliográficos
Autores principales: Barzegar, Mansoureh, Stokes, Karen Y., Chernyshev, Oleg, Kelley, Roger E., Alexander, Jonathan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615891/
https://www.ncbi.nlm.nih.gov/pubmed/34829896
http://dx.doi.org/10.3390/biomedicines9111667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615891/
https://www.ncbi.nlm.nih.gov/pubmed/34829896
http://dx.doi.org/10.3390/biomedicines9111667

Ejemplares similares